The Lustgarten Foundation Awards $5 Million Grant to Break Through Cancer
The Lustgarten Foundation has awarded a $5 million grant to Break Through Cancer to target KRAS in pancreatic cancer.
Two New Immunotherapy Trials Aim to Make Therapy More Effective
Two clinical trials in the Lustgarten Foundation’s Clinical Accelerator are testing different combinations of immunotherapy.
New Clinical Accelerator Initiative Shortens Time from Bench to Clinic
Dr. Elizabeth Jaffee explains the importance of Lustgarten’s Clinical Accelerator Initiative to speed up the time from bench to trial.
A Second Opinion: Important for Pancreatic Cancer Patients
Facing a new reality of having one of the toughest-to-treat cancers can indeed be overwhelming. That’s why it’s so important to make sure your treatment plan is the best possible one for you, say experts. One way to do that is with a second opinion. The reasons why pancreatic cancer patients seek second opinions are…
New Guidelines on the Use of Radiation for Pancreatic Cancer Treatment
New clinical guidelines from the American Society for Radiation Oncology will help clarify the best uses of radiation treatment for pancreatic cancer.
Dousing Out-of-Control KRAS Signaling in Pancreatic Cancer
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
Genetic Sequencing of Advanced Pancreatic Cancer Enables Personalized Medicine
Dr. Brian Wolpin has found that about 1/3 of pancreatic cancer patients may benefit from genetic sequencing to determine treatment.
Organoids Accurately Predict Treatment Response of Pancreatic Cancer Patients
An international team of researchers led by Dr. David Tuveson has found that organoids can predict how pancreatic cancer patients will respond to different treatments.
Lustgarten Foundation Appoints David Tuveson, M.D., Ph.D., Chief Scientist
Dr. David Tuveson has been appointed the chief scientist for the Lustgarten Foundation. He specializes in pancreatic cancer reseach at the Cold Spring Harbor Labs.